Komori
Enplas (6961) · RiskMitigated

Recognition of an allowance for doubtful accounts on short-term loans to a subsidiary

First written in FY2024-Q1. 2 of 4 entries say "Worsened", first in FY2024-Q2. Latest entry: FY2025-H1.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024-Q1WorsenedFY2024-Q2 – FY2024-Q32023: 220232024: 22024
Same theme, other companies
Recognition of an allowance for doubtful accounts on loans to affiliatesA theme 29 companies write about · 29 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 11 of 18 companies on the "Worse" side.

4 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 29 companies compared. The sentences above are computed from all 29.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1MitigatedAnnual report

    「貸倒引当金繰入額 161 -」

    子会社短期貸付金について、前年同期に161百万円計上されていた貸倒引当金繰入額は、当中間連結会計期間には計上されていない。
  2. FY2024-Q3WorsenedAnnual report

    「当社連結子会社の短期貸付金について、貸付先の財政状態等を踏まえ、個別に回収可能性を検討した結果、当該短期貸付金全額について、貸倒引当金繰入額162百万円として特別損失に計上いたしました。」

    子会社短期貸付金全額を対象とする貸倒引当金繰入額は162百万円となり、前回開示の161百万円から増加している。
  3. FY2024-Q2WorsenedAnnual report

    「当社連結子会社の短期貸付金について、貸付先の財政状態等を踏まえ、個別に回収可能性を検討した結果、当該短期貸付金全額について、貸倒引当金繰入額161百万円を特別損失に計上しております。」

    子会社短期貸付金について、全額を対象とする貸倒引当金繰入額161百万円を計上した。前回開示の157百万円から引当額が増加している。
  4. FY2024-Q1First statedAnnual report

    「当社連結子会社の短期貸付金について、貸付先の財政状態等を踏まえ、個別に回収可能性を検討した結果、当該短期貸付金全額について、貸倒引当金繰入額157百万円を特別損失に計上しております。」

    子会社の短期貸付金について回収可能性を検討した結果、全額に相当する157百万円の貸倒引当金繰入額を特別損失として計上したことを初めて開示している。
Moved together

"Fixed-asset valuation risk associated with early commercialization and licensing estimates for the Life Science business" moved the same way as this thread, in the same document, in 3 of its 4 moves.

3322★1234
  1. ★This thread
  2. 1Fixed-asset valuation risk associated with early commercialization and licensing estimates for the Life Science business3×
  3. 2Commercializing the biotechnology-related business and collaborating with DNA Chip Research Inc.3×
  4. 3Revenue growth but lower profit in the semiconductor equipment business2×
  5. 4Concern over a decline in semiconductor demand, particularly for memory applications2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Enplas's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Recognition of an allowance for doubtful accounts on short-term loans to a subsidiary | ENPLAS CORPORATION (6961) | Komori